Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study

BACKGROUND: The 0.2 µg/day fluocinolone acetonide (FAc) implant delivers continuous, low-dose, intravitreal corticosteroid for the treatment of diabetic macular oedema (DMO). This ongoing, 3-year, observational clinical trial provides long-term, ‘real-world’ safety results for the FAc implant in DMO...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansour, Sam E, Kiernan, Daniel F, Roth, Daniel B, Eichenbaum, David, Holekamp, Nancy M, Kaba, Samer, Werts, Erica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907551/
https://www.ncbi.nlm.nih.gov/pubmed/32461262
http://dx.doi.org/10.1136/bjophthalmol-2020-315984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907551/
https://www.ncbi.nlm.nih.gov/pubmed/32461262
http://dx.doi.org/10.1136/bjophthalmol-2020-315984

Ejemplares similares